Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A phase 1 study reporting a preliminary signal of activity in a molecular subtype (KRAS-mutant NSCLC, n=11) with a small sample, surrogate endpoint (progression-free status at 12 weeks), and no established clinical efficacy in unselected patients.
A single case report describing clinical response to tirzepatide in an adult with Prader–Willi syndrome and refractory diabetes; lacks comparison group, quantified outcomes, and generalizability.
A single-centre, mechanistic study identifying a gene target for β-cell transdifferentiation with proof-of-concept in primary human cells and mouse transplantation, but lacking human clinical data and requiring confirmation in larger systems.
International Journal of Innovative Technologies in Social Science
A qualitative literature review summarizing mechanistic evidence and observational studies on SGLT2 inhibitors in neurodegenerative disease; raises questions about neuroprotective potential but reports no primary clinical trial data or effect sizes to support practice change.
This is a mechanistic synthesis and conceptual reframing of pancreatitis pathophysiology based on preclinical genetically engineered mouse models, raising a network-based hypothesis rather than reporting a clinical trial or definitive human evidence.
A literature review summarizing clinical development, technical principles, and experimental results of cell therapy approaches for diabetes, offering a reference for research and clinical translation rather than reporting primary evidence.
The Journal of Clinical Endocrinology & Metabolism
A narrative mini-review synthesizing meta-analytic evidence on diabetes clustering in East Asians, proposing subtype-guided clinical strategies without presenting new primary data or a systematic methodology.
A narrative review synthesizing evidence on GLP-1RA mechanisms and effects across cardiometabolic domains, offering clinical perspective rather than reporting original trial data or a systematic quantitative synthesis.